ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2138

DXA-derived 3D Parameters of the Hip Discriminate Prevalent Fragility Fractures in Individuals with Axial Spondyloarthritis

Edgar Wiebe1, Elisa Schilling2, Dörte Huscher2, Zhivana Boydzhieva3, andriko Palmowski4, Sandra Hermann5, burkhard Muche5, Gerhard Krönke5 and FRANK HARTMUT DR. BUTTGEREIT1, 1Charité University Medicine Berlin, Berlin, Germany, 2Charité-Universitätsmedizin Berlin, Berlin, Germany, 3Charité Universittsmedizin, Berlin, Germany, 4Charité - Universittsmedizin Berlin, Berlin, Germany, 5Rheumatology, Charité, Berlin, Germany

Meeting: ACR Convergence 2024

Keywords: Ankylosing spondylitis (AS), Fracture, osteoporosis, risk factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Axial spondyloarthritis (axSpA) is associated with osteoporosis and fragility fracture risk that may not be reflected by areal bone mineral density (aBMD) measurements alone. DXA-derived three-dimensional (3D) analysis has emerged as a promising method for assessing structural bone properties of the femur, showing good correlation with quantitative computed tomography (1).
We aimed to investigate the discriminative performance of DXA-derived 3D parameters of the femur in comparison to aBMD and trabecular bone score (TBS) for pre-existent fragility fractures (FFx).

Methods: This cross-sectional analysis is part of the Rh-GIOP prospective observational cohort study focusing on bone health in inflammatory rheumatic diseases. We analyzed baseline visits of axSpA patients fulfilling the ASAS 2009 classification criteria. Using 3D-Shaper software (v2.12, 3D-Shaper Medical, Barcelona, Spain), we derived several parameters (integral, trabecular and cortical volumetric BMD, cortical thickness and cortical surface BMD) from hip DXA scans. Logistic regression analysis was used to develop discrimination models incorporating DXA-based T-scores, TBS, and 3D-Shaper parameters to detect prevalent FFx, vertebral fractures (VFx), and non-vertebral fractures (NVFx). Area under the curve (AUC) with 95% confidence intervals were calculated.

Results: Eighty patients with axSpA (64% male) were analyzed. The prevalence of FFx was 34%, and 15% had a history of VFx. DXA T-scores showed AUC values of 0.62 (0.48; 0.75), 0.54 (0.39; 0.70), and 0.64 (0.50; 0.78) for any FFx, VFx, and NVFx, respectively. DXA-derived 3D parameters showed better discrimination for fragility fractures, with AUC values of 0.75 (0.64; 0.86), 0.81 (0.69; 0.94), and 0.72 (0.59; 0.85). Incorporating these parameters in a logistic regression model with DXA and TBS further improved the discriminative ability (any FFx: AUC 0.78 (0.67; 0.89), VFx: AUC 0.86 (0.74; 0.98), NVFx: AUC 0.75 (0.63; 0.88)). TBS alone or in combination with DXA did not improve the discrimination of the model.

Conclusion: Our results suggest that DXA-derived 3D hip parameters offer superior discrimination of pre-existent FFx compared to DXA or TBS alone in patients with axSpA. Future longitudinal analysis will determine whether DXA-derived 3D femoral parameters can improve fracture prediction in clinical practice.


Disclosures: E. Wiebe: EW reports consultancy fees, honoraria and travel expenses from Novartis, 12, EW reports consultancy fees, honoraria and travel expenses from Novartis; E. Schilling: None; D. Huscher: None; Z. Boydzhieva: None; a. Palmowski: Novartis, 2; S. Hermann: None; b. Muche: BM received consulting and speaker honoraria and/or congress support from UCB Pharma Germany, Amgen Germany, Stadapharm, 12, BM received consulting and speaker honoraria and/or congress support from UCB Pharma Germany, Amgen Germany, Stadapharm; G. Krönke: Kyverna Therapeutics Inc, 5, 6; F. DR. BUTTGEREIT: AbbVie, 2, 5, 6, Gruenenthal, 2, Horizon Therapeutics, 2, 5, Pfizer, 6, Sanofi, 2, 5, 6, Sparrow Pharmaceuticals, 1, 5.

To cite this abstract in AMA style:

Wiebe E, Schilling E, Huscher D, Boydzhieva Z, Palmowski a, Hermann S, Muche b, Krönke G, DR. BUTTGEREIT F. DXA-derived 3D Parameters of the Hip Discriminate Prevalent Fragility Fractures in Individuals with Axial Spondyloarthritis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/dxa-derived-3d-parameters-of-the-hip-discriminate-prevalent-fragility-fractures-in-individuals-with-axial-spondyloarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/dxa-derived-3d-parameters-of-the-hip-discriminate-prevalent-fragility-fractures-in-individuals-with-axial-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology